Stock AYTU AYTU BIOSCIENCE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Aytu Bioscience Inc Share Price OTC Bulletin Board

Equities

AYTU

US0547542052

Pharmaceuticals

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Aytu Bioscience Inc
15/05 Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024
15/05 Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M MT

Financials

Sales 2024 * 81.33M 6.78B Sales 2025 * 78.22M 6.52B Capitalization 17.76M 1.48B
Net income 2024 * -13M -1.08B Net income 2025 * 4M 333M EV / Sales 2024 * 0.22 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.23 x
P/E ratio 2024 *
-1.22 x
P/E ratio 2025 *
3.94 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.43%
More Fundamentals * Assessed data

Latest news about Aytu Bioscience Inc

Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M MT
Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M MT
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Transcript : Aytu BioPharma, Inc., Q1 2024 Earnings Call, Nov 14, 2023
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party MT
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement CI
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M MT
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023 CI
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields DJ
More news

Latest transcript on Aytu Bioscience Inc

Logo Aytu Bioscience Inc
Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024
More transcripts

Analyst Recommendations on Aytu Bioscience Inc

Maxim Starts Aytu BioPharma at Buy With $5 Price Target MT
HC Wainwright Adjusts Price Target on Aytu BioPharma to $6 From $11, Reiterates Buy Rating MT
Cantor Fitzgerald Lowers Aytu BioPharma's Price Target to $5 From $11, Maintains Overweight Rating MT
HC Wainwright Adjusts Aytu BioScience's Price Target to $11 from $24, Keeps Buy Rating MT
AYTU BIOPHARMA : Cantor Fitzgerald Starts Aytu BioPharma at Overweight With $11 Price Target MT
More recommendations

Press releases Aytu Bioscience Inc

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 AQ
Aytu BioPharma to Present at LD Micro Main Event XVI Conference AQ
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority AQ
AYTU BIOPHARMA, INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) AQ
Aytu BioPharma : Presentation PU
More press releases

Managers and Directors - Aytu Bioscience Inc

Managers TitleAgeSince
Joshua Disbrow CEO
 Chief Executive Officer 49 16/15/16
Jarrett Disbrow FOU
 Founder 49 16/15/16
Mark Oki DFI
 Director of Finance/CFO 55 17/22/17
Members of the board TitleAgeSince
Vivian Liu BRD
 Director/Board Member 62 01/22/01
Jarrett Disbrow FOU
 Founder 49 16/15/16
Joshua Disbrow CEO
 Chief Executive Officer 49 16/15/16
More insiders

Company Profile

Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
Sector
Pharmaceuticals
Calendar
10:45pm - Lytham Partners Spring Investor Conference
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.22% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.57% 592B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.85% 347B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.48% 319B
ABBVIE INC. Stock AbbVie Inc.
-0.12% 274B
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.55% 238B
NOVARTIS AG Stock Novartis AG
+6.65% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-6.09% 203B
PFIZER, INC. Stock Pfizer, Inc.
-3.37% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AYTU Stock
  4. AYTU Stock